Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
Quarterly revenue of $64.783, compared to $79.263 in the same period in 2022. Revenue's 44% YoY increase ($443,490 vs. $308,490) was eclipsed by higher cost of sales ($378,707 now vs. $229,227 then.)Braxia Scientific Corp. (OTC:BRAXF), owner of ketamine therapy clinics and KetaMD telemedicine services for depression and related disorders, has shared its interim financial statements for the three months ended June 30, 2023.
布拉夏科學公司(場外交易：BRAXF)，氯胺酮治療診所和科塔瑪遠端醫療服務對於抑鬱症和相關疾病，已經分享了截至2023年6月30日的三個月的中期財務報表。
In numbers:
在數字方面：
-
Cash held was $636.483 (CA$861,393) as of June 30, compared to $1.08 million by March 31, 2023 and $5.67 million by June 30, 2022.
-
Quarterly revenue of $64.783, compared to $79.263 in the same period in 2022. Revenue's 44% YoY increase ($443,490 vs. $308,490) was eclipsed by higher cost of sales ($378,707 now vs. $229,227 then.)
-
Quarterly operating expenses totaled $654.771, an almost 17% decrease from $783.859 in 2022's comparable period.
-
Quarterly net loss of $592,785, around 18% down from the $715,878 net loss of the comparable period in 2022.
-
Accumulated deficit of $86.3 million by June 30, 2023 compared to $76.7 million by June 30, 2022.
-
持有的現金截至6月30日為636.483美元(861,393加元)，而2023年3月31日為108萬美元，2022年6月30日為567萬美元。
-
季度收入64.783美元，而2022年同期為79.263美元。營收同比增長44%(443,490美元比308,490美元)被更高的銷售成本(現在是378,707美元，當時是229,227美元)蓋過了。
-
季刊運營費用總額為654.771美元，較2022年S同期的783.859美元減少了近17%。
-
季刊淨虧損為592,785美元，較2022年同期的715,878美元淨虧損約18%。
-
累計赤字到2023年6月30日為8,630萬美元，而到2022年6月30日為7,670萬美元。
Together with the financial statements, the company's management published a discussion and analysis document regarding the quarter's results.
與財務報表一起，公司管理層發佈了一份討論與分析有關本季度業績的檔案。
CEO Dr. Roger McIntyre says that, while Braxia continues to face challenges "including in accessing capital through public markets," the fiscal year's first quarter brought in increasing clinical demand from new referrals for ketamine treatments.
首席執行官羅傑·麥金太爾博士他說，雖然Bracia繼續面臨挑戰，“包括通過公開市場獲得資本”，但本財年第一季度帶來了越來越多的對氯胺酮治療的新轉診的臨床需求。
This has in turn increased Braxia's patient base and treatment volumes across its clinics, a goal the company is taking ahead along with making "further progress" in reducing expenses and improving efficiencies.
這反過來又增加了Bracia的患者基礎和整個診所的治療量，該公司正在推進這一目標，同時在降低費用和提高效率方面取得“進一步進展”。
See Also: Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
另見：氯胺酮療法在家門口，越來越多的診所提供這種治療選擇
As for potential strategic partnerships within the context of a "challenging environment" in capital access, McIntyre says the team is currently involved in several discussions.
至於潛在的戰略合作夥伴關係，在資本獲取的“具有挑戰性的環境”的背景下，麥金太爾說，該團隊目前正在參與幾個討論。
"The company maintains its priorities and growth objectives. However, it also continues to look to access alternative sources of capital as well as seek other partnerships to support our growth objectives," he acknowledged. "If we are unable to raise additional funding in the short term, we will look at alternate courses of actions including, but not limited to, further cost reductions, restructuring and the potential scaling back of clinic locations."
“該公司維持其優先事項和增長目標。然而，它也繼續尋求其他資金來源，以及尋求其他合作夥伴關係，以支持我們的增長目標，”他承認。如果我們無法在短期內籌集更多資金，我們將考慮其他行動方案，包括但不限於進一步降低成本、重組和可能縮減診所地點。
Interested in other natural medicines markets? Our acclaimed Cannabis Capital Conference is coming up! Whether to close your deals or just get acquainted with the sector's best, come join us this Sept. 27-28 in Chicago for our 17th edition! Tickets HERE.
對其他天然藥物市場感興趣嗎？我們廣受好評的大麻之都會議馬上就要到了！無論是完成您的交易，還是隻是瞭解行業最好的產品，請於今年9月加入我們的行列。27-28在芝加哥為我們的第17屆！門票在這裡。
Photo: Benzinga edit with photo by Andrea Piacquadio by Pexels and DanielTahar on Wikimedia Commons.
圖片：Benzinga編輯由Pexels和DanielTahar在Wikimedia Commons上由Andrea Piacquadio拍攝
